GSK wins FDA approval for lung cancer drug Nelkarmi
GSK received FDA approval for its lung cancer drug Nelkarmi, targeting ALK gene mutations. The approval follows GSK's $10.6B acquisition of Nuvalent. Analysts estimate $1B in 2032 sales. GSK aims to expand its oncology portfolio under CEO Luke Miels.
How this was made
The 30-second read
Why it matters
This is a regulatory milestone that reduces clinical and approval risk for GSK’s ALK-mutant NSCLC program, but the article flags that confirmatory late-stage benefits are still pending.
Market read
Traders may reassess GSK’s oncology pipeline quality and near-term commercialization expectations following a new FDA approval tied to a recent acquisition.
What to watch
Commercial traction will depend on sequencing versus existing ALK therapies, payer coverage decisions, and results from the ongoing late-stage study that could confirm or dilute the early-stage benefit.
Background
GSK’s FDA approval for neladalkib (Nelkarmi) follows its $10.6B Nuvalent acquisition, which also delivered another approved drug (Jideytro).
Ticker impact
GSK received FDA approval for its lung cancer drug Nelkarmi (neladalkib), validating its Nuvalent acquisition and expanding its oncology pipeline.
Likely upward bias as the market prices in commercialization optionality and reduced regulatory risk, tempered by uncertainty around full late-stage benefit.
The article reports a new FDA approval and links it directly to GSK’s Nuvalent acquisition, which is a concrete, decision-grade catalyst; it also notes an ongoing late-stage study, limiting certainty on ultimate efficacy and uptake.
Market effects
Strengthens the ALK-driven lung cancer competitive set and highlights continued value creation from oncology M&A and accelerated approvals.
Supports UK pharma sentiment via a US regulatory milestone.
US FDA approvals can re-rate global pharma oncology pipelines and influence peer expectations for ALK-targeted development.
Counterpoint
Accelerated approval may not translate into durable label expansion or strong uptake if confirmatory trials underperform or if safety/tolerability limits adoption versus existing ALK drugs.
Key entities
- companyGSK
Received FDA approval for Nelkarmi (neladalkib) for ALK-driven non-small cell lung cancer.
- companyNuvalent
Biotechnology acquired by GSK; its rights underpin the Nelkarmi approval.
- regulatorFDA
Granted accelerated approval for the specified NSCLC indication.




